Advertisement
  • An Emerging Treatment for Metastatic Prostate Cancer

    A drug that delivers radioactive particles to prostate cancer cells increases overall survival for metastatic castration-resistant prostate cancer.

    by Pamela Rafalow Grossman

  • August 27: The Week in Cancer News

    Regular exercise can help mitigate cognitive problems associated with chemotherapy, and researchers learn more about the link between cholesterol and cancer.

    by Bradley Jones

  • August 20: The Week in Cancer News

    Patient volume at radiation therapy clinics can affect outcomes, and experts call attention to a third breast cancer gene, PALB2.

    by Marci A. Landsmann

  • August 13: The Week in Cancer News

    Survival is not affected by delaying breast cancer treatment for fertility preservation, and the FDA approves a drug combination to treat kidney cancer.

    by Kevin McLaughlin

  • Drug Delays Recurrence in People With Early-Stage Breast Cancer

    People who have inherited BRCA mutations and are at high risk for cancer recurrence may benefit from a PARP inhibitor.

    by Pamela Rafalow Grossman

  • July 30: The Week in Cancer News

    Healthy lifestyle habits can reduce risk of cancer, and less treatment may be adequate for some children with ALL.

    by Marci A. Landsmann

  • July 23: The Week in Cancer News

    Two studies on access to opioids identify disturbing patterns, and Keytruda before and after surgery helps some breast cancer patients.

    by Kevin McLaughlin

  • Remote Care

    After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs' value for cancer patients undergoing treatment.

    by Jon Kelvey

  • July 16: The Week in Cancer News

    A study measures the global impact of alcohol on cancer incidence, and the FDA approves treatments for multiple myeloma and urothelial cancer.

    by Bradley Jones

  • Moving Away From the Maximum Tolerated Dose

    The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate.

    by Marcus A. Banks